Previous 10 | Next 10 |
Total Revenues for Fiscal Year 2022 of $129.3 Million Represent ed Growth of 25% Compared to Fiscal Year 2021 ; Fourth Quarter 2022 Revenues of $45. 4 Million Represent ed a 44% Increase Year - over - Year Fiscal Year 2022 EBITDA ...
REHOVOT, Israel and HOBOKEN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, toda...
FDA Approval Currently Expected by Mid-2023 Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50% Ability to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency REHO...
REHOVOT, Israel and HOBOKEN, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that its Chief Financial Officer (CFO), Chaime Orlev, will tr...
Third Quarter 2022 Revenues of $32.2 Million , a 40% Increase Compared to Prior Year Period; Reaping the Benefits of the Acquired IgG Portfolio Strong Results Represent Completion of the Company’s Strategic Transformation into a Diversified Commercial Entity with ...
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the third quart...
Trial Recruitment Beginning to Accelerate ; 30 Patients Enrolled and Treated to Date Independent Data Safety Monitoring Board (DSMB) Recommends Study Continu ation Without Modification for Fourth Time Since Study Initiation Based on ...
REHOVOT, Israel and HOBOKEN, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that Amir London, Chief Executive Officer, will present a c...
Kamada ( NASDAQ: KMDA ) was awarded an extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG® and WINRHO® SDF, for an additional three years for an approximate total value of ...
Awarded Extension to Existing Supply Tender which relates to Portfolio of Four Specialty IgG Products Acquired in 2021 Supply Extension Secures Ongoing Sales of Approximately $7.5 Million Per Year for 2023-2025, with an Option to Extend for up to Additional Two Years R...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 04:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...